Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
← catalyst calendarSponsored by Omeros Corporation (industry) · OMER — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
15actual
Sites
1
Country
Ukraine
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-09 | actual | When the study began enrolling |
| Primary completion | 2025-11-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-03 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Hemoglobinuria
Intervention
- Biological: OMS906 — also filed as zaltenibart
Primary outcome
what the primary-completion date above is the date OFTo Assess the Overall Safety and Tolerability of Zaltenibart (OMS906) Administration in PNH patients
measured 48 weeks
Permalink · OMER's whole pipeline · Catalyst calendar · Every registered study · What changed